Iris Jacobs
About
Iris Jacobs is a scholar working on Genetics, Hematology and Molecular Biology.
According to data from OpenAlex, Iris Jacobs has authored 34 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 16 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Iris Jacobs's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (18 papers), Hemophilia Treatment and Research (15 papers) and Platelet Disorders and Treatments (8 papers). Iris Jacobs is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (18 papers), Hemophilia Treatment and Research (15 papers) and Platelet Disorders and Treatments (8 papers). Iris Jacobs collaborates with scholars based in United States, Germany and Italy. Iris Jacobs's co-authors include C. Voigt, Pamela S. Puttfarcken, Elena Santagostino, Claude Négrier, Connie R. Faltynek, Massimo Morfini, Andreas Tiede, Ingrid Pabinger-Fasching, Robert Klamroth and U. Martinowitz and has published in prestigious journals such as Blood, Brain Research and Journal of Allergy and Clinical Immunology.
In The Last Decade
Iris Jacobs
26 papers receiving 724 citations
Peers
Iris Jacobs
Annemarie Koch Germany
AC Ludolph Germany
Darren D. O’Rielly Canada
Anjali Kumar United States
Ye Jee Shim South Korea
M. Shawi United States
Sibel Oğuzkan Balcı Türkiye
Hatsumi Yamamoto Japan
N. D. Ryan United States
James D. Weisfeld‐Adams United States
Citations per year, relative to Iris Jacobs Iris Jacobs (= 1×)
peers
Annemarie Koch
Countries citing papers authored by Iris Jacobs
Since
Specialization
Citations
This map shows the geographic impact of Iris Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Jacobs more than expected).
Fields of papers citing papers by Iris Jacobs
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Iris Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Jacobs. The network helps show where Iris Jacobs may publish in the future.
Co-authorship network of co-authors of Iris Jacobs
This figure shows the co-authorship network connecting the top 25 collaborators of Iris Jacobs. A scholar is included among the top collaborators of Iris Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Jacobs. Iris Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jacobs, Joshua, William R. Lumry, William H. Yang, et al.. (2025). Safety And Efficacy Of Garadacimab For Hereditary Angioedema Prophylaxis In Patients Aged ≥65 Years. Journal of Allergy and Clinical Immunology. 155(2). AB196–AB196.
2.
Cohn, Danny M., Petra Staubach, William R. Lumry, et al.. (2025). Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations. Journal of Allergy and Clinical Immunology. 156(6). 1756–1760.e4.
3.
Cohn, Danny M., Florence Ida Hsu, Raffi Tachdjian, et al.. (2025). Clinical Study Experience Suggests No Impact On Hemostasis Among Patients With Hereditary Angioedema Receiving Garadacimab And Undergoing Surgical/Medical Procedures. Journal of Allergy and Clinical Immunology. 155(2). AB211–AB211.
4.
Walsh, Sarah N., Yinglei Li, Iris Jacobs, et al.. (2025). Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. Journal of Comparative Effectiveness Research. 14(8). e240237–e240237.
5.
Walsh, Sarah N., Yinglei Li, Iris Jacobs, et al.. (2025). Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema. Drugs in R&D. 25(2). 161–178.
6.
Keith, Paul K., A. J. Roberts, Hamsaraj Shetty, et al.. (2024). LOW INCIDENCE OF GARADACIMAB IMMUNOGENICITY WITH NO IMPACT ON EFFICACY, SAFETY OR PHARMACOKINETICS: INTEGRATED ANALYSIS. Annals of Allergy Asthma & Immunology. 133(6). S32–S32.
7.
Craig, Timothy, Donald S. Levy, Avner Reshef, et al.. (2024). Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. The Lancet Haematology. 11(6). e436–e447.
8.
Sharma, Ankur, et al.. (2024). Population Pharmacokinetic/Pharmacodynamic Analysis Of Garadacimab, In Patients With Hereditary Angioedema. Journal of Allergy and Clinical Immunology. 153(2). AB4–AB4.
9.
Craig, Timothy, John Anderson, Joshua Jacobs, et al.. (2024). Integrated Safety And Efficacy Of Garadacimab For Hereditary Angioedema Prophylaxis Across 3 Clinical Trials: Phase 2, Pivotal Phase 3, And Open-Label Extension Studies. Journal of Allergy and Clinical Immunology. 153(2). AB256–AB256.
10.
Yamagami, Keiko, Yoshihiro Sasaki, Takashi Miyagi, et al.. (2023). Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study. Allergology International. 72(3). 451–457.
11.
Santagostino, Elena, U. Martinowitz, Toshko Lissitchkov, et al.. (2016). Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 127(14). 1761–1769.
12.
Chambost, Hérvè, Christoph Male, Thierry Lambert, et al.. (2016). Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Thrombosis and Haemostasis. 116(10). 659–668.
13.
Roberts, John, Debra M. Bensen-Kennedy, Iris Jacobs, et al.. (2016). Population pharmacokinetics of a new long‐acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. Journal of Thrombosis and Haemostasis. 14(11). 2132–2140.
14.
Lubetsky, Aaron, Toshko Lissitchkov, Elena Santagostino, et al.. (2013). Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B. Blood. 122(21). 1109–1109.
15.
Apers, Jan A., et al.. (2012). Perioperative outcomes of revisional laparoscopic gastric bypass after failed adjustable gastric banding and after vertical banded gastroplasty: experience with 107 cases and subgroup analysis. Surgical Endoscopy. 27(2). 558–564.
16.
Martinowitz, U., Aaron Lubetsky, Elena Santagostino, et al.. (2012). Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP). Blood. 120(21). 1121–1121.
17.
Jacobs, Iris, David J. Anderson, Carol S. Surowy, & Pamela S. Puttfarcken. (2002). Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration. Neuropharmacology. 43(5). 847–856.
18.
Puttfarcken, Pamela S., Iris Jacobs, & Connie R. Faltynek. (2000). Characterization of nicotinic acetylcholine receptor-mediated [3H]-dopamine release from rat cortex and striatum. Neuropharmacology. 39(13). 2673–2680.
19.
Anderson, David J., Pamela S. Puttfarcken, Iris Jacobs, & Connie R. Faltynek. (2000). Assessment of nicotinic acetylcholine receptor-mediated release of [3H]-norepinephrine from rat brain slices using a new 96-well format assay. Neuropharmacology. 39(13). 2663–2672.
20.
Bitner, Robert S., Arthur L. Nikkel, Peter Curzon, et al.. (2000). Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Research. 871(1). 66–74.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Annemarie Koch Breakdown of academic impact, for papers by AC Ludolph Breakdown of academic impact, for papers by Darren D. O’Rielly Breakdown of academic impact, for papers by Anjali Kumar Breakdown of academic impact, for papers by Ye Jee Shim Breakdown of academic impact, for papers by M. Shawi Breakdown of academic impact, for papers by Sibel Oğuzkan Balcı Breakdown of academic impact, for papers by Hatsumi Yamamoto Breakdown of academic impact, for papers by N. D. Ryan Breakdown of academic impact, for papers by James D. Weisfeld‐Adams